Montreal hosts the 4th International Symposium on Arthrogryposis Multiplex Congenita (AMC)

1 year ago

4th International Symposium on Arthrogryposis Montreal welcomes scientists from around the world for the 4th International Symposium on Arthrogryposis MONTREAL,…

Impact BioMedical Inc. (NYSE: IBO) Announces 3F™ US Patent Issue

1 year ago

HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (“IBO”) is pleased to announce that the US Patent and…

Gynesonics Announces New SMART OS™ Software Technology for Sonata® System Treatment of Uterine Fibroids

1 year ago

Revolutionizing Fibroid Treatment with Enhanced Precision, Control & FlexibilityREDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gynesonics Inc., a…

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

1 year ago

CUPERTINO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…

Kane Biotech Announces Attendance at Upcoming Wound Care Conferences

1 year ago

WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”)…

Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

1 year ago

Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

1 year ago

GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have…

Nuvo Group Retains Intrepid Investment Bankers to Explore Investment and Strategic Alternatives

1 year ago

TEL AVIV, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Holdco Nuvo Group D.G Ltd (“Nuvo”), a pioneer in remote pregnancy…

Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis

1 year ago

SYRACUSE, New York, VANCOUVER, British Columbia, and BASEL, Switzerland, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Repair Biotechnologies, a biotechnology company…